November 18, 2026
Health news, explained with evidence
LIVE

Early Eosinophilic Esophagitis Treatment May Lower Childhood Asthma Risk

❤️ Conditions & Care 2 min read 👁 9

An observational study suggests that administering the biologic dupilumab to young children with eosinophilic esophagitis before age 6 may reduce their subsequent risk of developing asthma.

Early Eosinophilic Esophagitis Treatment May Lower Childhood Asthma Risk❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • Children treated with dupilumab before age 6 showed a lower subsequent incidence of asthma.
  • The observational study analyzed data from a large commercial insurance database.
  • Researchers stress that randomized controlled trials are required to confirm causality.

A recent observational study presented at the American College of Allergy, Asthma & Immunology annual meeting suggests that early treatment of eosinophilic esophagitis with the biologic medication dupilumab (Dupixent) is linked to a lowered risk of developing asthma later in childhood. Researchers utilized a large commercial insurance database to examine children who started the therapy before turning 6 years old and remained off it for at least a year afterward. Among this group, 8.1% developed asthma over a subsequent 3.5-year period, compared with 16.0% of children with eosinophilic esophagitis who never received the medication.

Led by Kayla J. Steinberger, MD, PhD, of West Virginia University, the investigation explored whether early biological therapy might alter the progression of the atopic march—the natural progression of allergic diseases in childhood driven by Type 2 inflammation. Dupilumab works by inhibiting interleukin 4 and 13 signaling pathways, which affect multiple cell types across different organ systems. While the findings point toward a potential protective effect, the study's retrospective and observational design means it can only generate hypotheses rather than establish direct cause and effect. Experts note that factors such as residual confounding, disease severity, and medication adherence could have influenced the outcomes.

What to know: While the results offer a promising look at managing multisystem allergic conditions early in life, researchers emphasize the need for prospective trials and independent longitudinal studies to validate these conclusions. Patients and caregivers should always consult a qualified healthcare provider before making personal medical or treatment decisions.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/acaai/123889 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.